Patient Preference and Adherence (Aug 2012)

Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients

  • Zecca C,
  • Yawalkar N,
  • Gobbi C

Journal volume & issue
Vol. 2012, no. default
pp. 565 – 567

Abstract

Read online

Chiara Zecca,1 Nikhil Yawalkar,2 Claudio Gobbi11Neurocenter of Southern Switzerland, Lugano, 2Department of Dermatology, Bern University Hospital, Bern, SwitzerlandBackground: The spectrum of side effects related to interferon beta-1b (INF-1b) treatment may compromise long-term adherence.Methods: Five INF-1b-treated multiple sclerosis patients with poor skin tolerability and clinical stability were instructed to dissolve the established (250 µg) INF-1b dose in half (0.5 mL) the standard diluent (1.0 mL, 0.54% sodium chloride solution), and were followed for 9 months.Results: Halving the volume of the treatment diluent was associated with significant improvement of skin side effects profile in all patients. The improvement was sustained for 9 months.Conclusion: Halving the volume of the INF-1b diluent could represent a different strategy to optimize skin tolerability and adherence in some multiple sclerosis patients.Keywords: multiple sclerosis, interferon, treatment tolerability, side effects, skin reactions